#South Korea #Seoul #Lilly #ABL Bio #Grabody

ABL Bio Secures Major Investment from Eli Lilly

ABL Bio, a leading company in the bispecific antibodies industry, has recently announced a groundbreaking agreement with Eli Lilly and Company. The deal consists of two essential components: a $40 million upfront payment and an additional $15 million equity investment from Lilly. This $55 million funding will greatly accelerate ABL Bio's research and development (R&D) efforts on its innovative Grabody platform, which focuses on creating advanced therapeutic candidates.

The collaboration aims to leverage the cutting-edge technology of the Grabody platform across various therapeutic modalities. ABL Bio and Lilly are currently working together to explore multiple treatment options that address various unmet medical needs. According to ABL Bio's CEO, Sang Hoon Lee, the newly acquired funding will enable the company to significantly expand the therapeutic indications of the Grabody platform, particularly in areas such as obesity and muscle disorders. These areas are noted for their high demand for effective treatments, showcasing ABL Bio's commitment to addressing critical health challenges.

In the context of this agreement, Sang Hoon Lee commented on the importance of the partnership, stating that after fulfilling all necessary administrative procedures, including compliance with the HSR Act, ABL Bio is set to receive the significant upfront payment along with equity investment from Lilly. The company's strategic plans include enhancing the clinical development of bispecific immuno-oncology candidates and pushing the boundaries of next-generation antibody-drug conjugates (ADCs).

Moreover, on November 12 and 14, ABL Bio officially inked a license, research, and collaboration agreement that valued at approximately $2.602 billion. This extensive agreement reflects both companies' long-term vision for developing novel therapies to improve patient outcomes. With Lilly’s backing and ABL Bio’s innovative research methods, there is great potential for the development of highly effective treatments in the pharmaceutical landscape.

ABL Bio's existing pipeline showcases its ambitious approach to biopharmaceutical development. The company is currently running clinical projects involving eight pipelines, which include:

• - ABL301 (SAR446159)
• - ABL001 (tovecimig)
• - ABL111 (givastomig)
• - ABL503 (ragistomig)
• - ABL105 (YH32367)
• - ABL104 (YH32364)
• - ABL103
• - ABL202 (CS5001/LCB71)

These projects span various indications and international collaborations, representing ABL Bio's commitment to advancing global healthcare solutions.

In addition to its innovative pipeline, ABL Bio is closely monitoring the completion of Phase 1 clinical trials and exploring future collaborations with other major pharmaceutical players. For instance, Sanofi will take over subsequent clinical studies for ABL301. Furthermore, ABL001 has achieved Fast Track designation from the U.S. Food and Drug Administration (FDA), reflecting the urgency and promise of its development in treating serious conditions.

Notably, ABL111, co-developed with NovaBridge, has demonstrated promising results in clinical trials where it was combined with nivolumab and chemotherapy, highlighting the effectiveness of ABL's research in immunotherapy settings.

As ABL Bio forges ahead, its direction under the collaboration with Lilly will likely redefine its approach to clinical research and development, offering hope for countless patients worldwide looking for groundbreaking therapies. With a robust strategy, an innovative portfolio, and a strong partnership, ABL Bio is positioning itself at the forefront of biopharmaceutical innovation. Stay tuned for further developments as this collaboration progresses and its impact on patient care unfolds.